Collectively, these data suggest that the designed compounds have very good tumor selectivity indexes, and antiangiogenic properties, exhibit good inhibition of CD11b expression, and regulate pathways involved in CD8+ T-cell activity. The gene discussed is CD8A; the disease is neoplasm.